263 related articles for article (PubMed ID: 22011670)
1. Predictive value of intratumoral microvascular density in patients with advanced non-small cell lung cancer receiving chemotherapy plus bevacizumab.
Zhao YY; Xue C; Jiang W; Zhao HY; Huang Y; Feenstra K; Resau JH; Qian CN; Zhang L
J Thorac Oncol; 2012 Jan; 7(1):71-5. PubMed ID: 22011670
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of microvascular density for response to anlotinib in advanced NSCLC.
Liu D; Ding G
Medicine (Baltimore); 2022 Jan; 101(3):e28647. PubMed ID: 35060554
[TBL] [Abstract][Full Text] [Related]
3. Two distinct types of blood vessels in clear cell renal cell carcinoma have contrasting prognostic implications.
Yao X; Qian CN; Zhang ZF; Tan MH; Kort EJ; Yang XJ; Resau JH; Teh BT
Clin Cancer Res; 2007 Jan; 13(1):161-9. PubMed ID: 17200351
[TBL] [Abstract][Full Text] [Related]
4. Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.
Heist RS; Duda DG; Sahani DV; Ancukiewicz M; Fidias P; Sequist LV; Temel JS; Shaw AT; Pennell NA; Neal JW; Gandhi L; Lynch TJ; Engelman JA; Jain RK
Proc Natl Acad Sci U S A; 2015 Feb; 112(5):1547-52. PubMed ID: 25605928
[TBL] [Abstract][Full Text] [Related]
5. Adverse cardiovascular events predict survival benefit in non-small lung cancer patients treated with bevacizumab.
Koyama N
Cancer Biomark; 2014; 14(4):259-65. PubMed ID: 24934369
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer.
Mineo TC; Ambrogi V; Baldi A; Rabitti C; Bollero P; Vincenzi B; Tonini G
J Clin Pathol; 2004 Jun; 57(6):591-7. PubMed ID: 15166262
[TBL] [Abstract][Full Text] [Related]
7. Imaging proliferation of ¹⁸F-FLT PET/CT correlated with the expression of microvessel density of tumour tissue in non-small-cell lung cancer.
Yang W; Zhang Y; Fu Z; Sun X; Mu D; Yu J
Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1289-96. PubMed ID: 22581165
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of angiogenesis in non-small cell lung carcinoma by CD34 immunohistochemistry.
Bing Z; Jian-ru Y; Yao-quan J; Shi-feng C
Cell Biochem Biophys; 2014 Sep; 70(1):327-31. PubMed ID: 24676677
[TBL] [Abstract][Full Text] [Related]
10. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
Cohen MH; Gootenberg J; Keegan P; Pazdur R
Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
[TBL] [Abstract][Full Text] [Related]
11. Correlation between Contrast-Enhanced Ultrasound and Microvessel Density via CD31 and CD34 in a rabbit VX2 lung peripheral tumor model.
Xing J; He W; Ding YW; Li Y; Li YD
Med Ultrason; 2018 Feb; 1(1):37-42. PubMed ID: 29400366
[TBL] [Abstract][Full Text] [Related]
12. The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease.
Shimizu R; Fujimoto D; Kato R; Otoshi T; Kawamura T; Tamai K; Matsumoto T; Nagata K; Otsuka K; Nakagawa A; Otsuka K; Katakami N; Tomii K
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1159-66. PubMed ID: 25245821
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naive patients with advanced nonsquamous non-small cell lung cancer.
Urata Y; Okamoto I; Takeda M; Hattori Y; Okuno K; Shimada T; Kurata T; Kaneda H; Miyazaki M; Terashima M; Tanaka K; Morita S; Nakagawa K; Negoro S; Satouchi M
Cancer; 2013 Jun; 119(12):2275-81. PubMed ID: 23558513
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab plus weekly paclitaxel with or without carboplatin for previously-treated non-squamous non-small cell lung cancer.
Hata A; Katakami N; Tanaka K; Takeshita J; Matsumoto T; Monden K; Nagata K; Masago K; Kaji R; Fujita S; Tachikawa R; Otsuka K; Otsuka K; Tomii K
Anticancer Res; 2014 Jan; 34(1):275-81. PubMed ID: 24403474
[TBL] [Abstract][Full Text] [Related]
15. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.
Zhou C; Wu YL; Chen G; Liu X; Zhu Y; Lu S; Feng J; He J; Han B; Wang J; Jiang G; Hu C; Zhang H; Cheng G; Song X; Lu Y; Pan H; Zheng W; Yin AY
J Clin Oncol; 2015 Jul; 33(19):2197-204. PubMed ID: 26014294
[TBL] [Abstract][Full Text] [Related]
16. Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
Spigel DR; Patel JD; Reynolds CH; Garon EB; Hermann RC; Govindan R; Olsen MR; Winfree KB; Chen J; Liu J; Guba SC; Socinski MA; Bonomi P
J Thorac Oncol; 2015 Feb; 10(2):353-9. PubMed ID: 25611228
[TBL] [Abstract][Full Text] [Related]
17. Number of circulating endothelial progenitor cells and intratumoral microvessel density in non-small cell lung cancer patients: differences in angiogenic status between adenocarcinoma histologic subtypes.
Maeda R; Ishii G; Ito M; Hishida T; Yoshida J; Nishimura M; Haga H; Nagai K; Ochiai A
J Thorac Oncol; 2012 Mar; 7(3):503-11. PubMed ID: 22198428
[TBL] [Abstract][Full Text] [Related]
18. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer.
Ciuleanu T; Tsai CM; Tsao CJ; Milanowski J; Amoroso D; Heo DS; Groen HJ; Szczesna A; Chung CY; Chao TY; Middleton G; Zeaiter A; Klingelschmitt G; Klughammer B; Thatcher N
Lung Cancer; 2013 Nov; 82(2):276-81. PubMed ID: 23992877
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysis.
Lopez-Chavez A; Young T; Fages S; Leon L; Schiller JH; Dowlati A; Brahmer JR; Johnson DH; Sandler A
J Thorac Oncol; 2012 Nov; 7(11):1707-12. PubMed ID: 23059774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
